Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04535856
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2020-08-28
Brief Title:
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients
Sponsor:
Ina-Respond
Organization:
Ina-Respond
Study Overview
Official Title:
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients Randomized Double-blind and Placebo-controlled
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DW-MSC
Brief Summary:
This is a phase 1 clinical trial to verify the safety and efficacy of DW-MSC in COVID-19 patients A total of 9 subjects are randomly allocated Subjects who meet the final inclusion and exclusion criteria are randomized to the test groups low-dose group and high-dose group or control group placebo group in a ratio of 111 Subjects assigned to the test groups were administered intravenously once with 5 x 107cells of DW-MSC for the low-dose group or 1 x 108cells for the high-dose group after registration Subjects assigned to the control group were administered with placebo in the same manner as the test drug DW-MSC At this time all of the existing standard co-treatment are allowed DW-MSC is adjunct therapy to standard therapy
This clinical trial is a double-blind trial in which a randomized method will be used To maintain the double-blindness of the study statistician who do not participate in this study independently generate randomization code Subjects will be randomized to the test groups low-dose group and high-dose group or the control group placebo group in a 111 ratio After the completion of the trial the randomization code will be disclosed after unlocking the database and unblinding procedures Follow Up period observed for 28 days after a single administration
This clinical trial is a double-blind trial in which a randomized method will be used To maintain the double-blindness of the study statistician who do not participate in this study independently generate randomization code Subjects will be randomized to the test groups low-dose group and high-dose group or the control group placebo group in a 111 ratio After the completion of the trial the randomization code will be disclosed after unlocking the database and unblinding procedures Follow Up period observed for 28 days after a single administration
Detailed Description:
Patients with Covid-19 have a mortality rate of about 35 50 and currently severe patients caused by the Coronavirus show respiratory distress To date the incidence rate has been more than 3 million each year however as the increase and globalization of the environmental pollution has been expanded the number of patients is expected to increase due to acute diseases such as the Middle East Respiratory virus SARS and coronavirus
Since 2015 Daewoong Pharmaceutical intends to use stem cells for product research on rare and intractable diseases including respiratory distress Stem cells are also called pluripotent cells or truncal cells that can convert to any organ It is an embryonic stage undifferentiated cell that has stopped differentiating before forming a specific organ whose differentiation has not been determined and has the ability to differentiate into muscle bone and internal conformal body organs There are three types of stem cells embryonic stem cells adult stem cells and induced pluripotent stem cells Daewoong Pharmaceutical intends to develop cell therapy products using mesenchymal stem cells MSC
Since 2015 Daewoong Pharmaceutical intends to use stem cells for product research on rare and intractable diseases including respiratory distress Stem cells are also called pluripotent cells or truncal cells that can convert to any organ It is an embryonic stage undifferentiated cell that has stopped differentiating before forming a specific organ whose differentiation has not been determined and has the ability to differentiate into muscle bone and internal conformal body organs There are three types of stem cells embryonic stem cells adult stem cells and induced pluripotent stem cells Daewoong Pharmaceutical intends to develop cell therapy products using mesenchymal stem cells MSC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1263-1723 | OTHER | WHO UTN Number | None |